Source: Virtual Congress 2021 – Bronchiectasis heterogeneity: assessing the endotypes



Rating:

Share or cite this content

Citations should be made in the following way:
E. Polverino (Barcelona, Spain), J. Chalmers (Dundee, United Kingdom), S. Aliberti (Milan, Italy), C. Haworth (Cambridge, United Kingdom), F. Blasi (Milan, Italy), W. Boersma (Alkmaar, Netherlands), A. De Soyza (Newcastle, United Kingdom), K. Dimakou (Athens, Greece), S. Elborn (Belfast, United Kingdom), M. Loebinger (London, United Kingdom), A. Torres (Barcelona, Spain), M. Shteinberg (Haifa, Israel), T. Welte (Hannover, Germany), M. Vendrell (Girona, Spain), F. Ringshausen (Hannover, Germany), R. Menendez (Valencia, Spain), A. Shoemark (Dundee, United Kingdom), P. Burgel (Paris, France), P. Goeminne (Nikolaas, Belgium). Inhaled corticosteroids use in patients with bronchiectasis: Data from the EMBARC registry. 1312

Member's Comments

No comment yet.

Related content which might interest you: Inhaled corticosteroids in COPD: the case against Source: Eur Respir J 2009; 34: 13-16 Year: 2009 Inhaled corticosteroids in COPD: the clinical evidence Source: Eur Respir J 2015; 45: 525-537 Year: 2015 Inhaled corticosteroids in COPD: a case in favour Source: Eur Respir J 2009; 34: 10-12 Year: 2009 Inhaled steroids prescribing in patients with COPD in the community Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience Source: ERJ Open Res, 8 (1) 00014-2022; 10.1183/23120541.00014-2022 Year: 2022 Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study Source: ERJ Open Res, 6 (1) 00246-2019; 10.1183/23120541.00246-2019 Year: 2020 Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD Source: Annual Congress 2012 - COPD: risk factors, biomarkers and diagnosis Year: 2012 Exacerbations and inhaled corticosteroids in bronchiectasis patients Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 Inhaled medication use in asthma and COPD Roma/Gypsies patients Source: Eur Respir J 2005; 26: Suppl. 49, 610s Year: 2005 Inhaled corticosteroids are over prescribed in patients with COPD, attending hospital Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006 Rationale for use of inhaled steroids in children with bronchiectasis Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Inhaled corticosteroids: a controversial add-on treatment in COPD Source: Eur Respir J 2010; 36: 973-974 Year: 2010 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019 Year: 2019 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019 Year: 2019 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009